Keros halts parts of Phase 2 PAH trial due to safety, stock tanks 70%
Keros Therapeutics said Thursday morning it has voluntarily halted two of three dosing arms of its experimental drug in a Phase 2 trial due to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
